Cocrystal Pharma
COCP
16 hedge funds and large institutions have $1.32M invested in Cocrystal Pharma in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.37% more ownership
Funds ownership: 6.56% → 6.92% (+0.37%)
17% less capital invested
Capital invested by funds: $1.59M → $1.32M (-$277K)
20% less funds holding
Funds holding: 20 → 16 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$144K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.6K |
| 3 |
Renaissance Technologies
New York
|
+$4.27K |
| 4 |
JP Morgan Chase
New York
|
+$3.24K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$241 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
-$36.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$22.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.68K |
| 4 |
CYG
Clean Yield Group
Norwich,
Vermont
|
-$999 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$660 |
COCP Hedge Fund Activity: Q3 2023 in Review
16 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q3 2023, worth a combined $1.32M — down 17% from $1.59M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of COCP and 0 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Susquehanna International Group, adding an estimated $144K. The largest seller was Parallel Advisors, exiting entirely with an estimated $36.4K sold.
- 16 institutional investors held Cocrystal Pharma (COCP) as of Q3 2023, down from 20 in Q2 2023.
- Funds reported $1.32M of Cocrystal Pharma stock for Q3 2023, down 17% quarter-over-quarter.
- 0 funds opened new Cocrystal Pharma positions in Q3 2023 and 4 closed out, a net change of -4 holders.
- The largest Cocrystal Pharma buyer in Q3 2023 was Susquehanna International Group, an estimated $144K added.
- The largest Cocrystal Pharma seller in Q3 2023 was Parallel Advisors, an estimated $36.4K sold.
Based on aggregated 13F filings for Q3 2023.